SCHEMBL10200459

SCHEMBL10200459

Cc1cc(OP(C)(=O)OCc2ccccc2)cc(-c2cc(OP(=O)(OCc3ccccc3)OCc3ccccc3)c3cc4c(cc3n2)OCO4)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 7/20 0.35
SMN1; SMN2 Q16637 5/20 0.35
NPC1 O15118 2/20 0.35
RAB9A P51151 1/20 0.35
ALDH1A1 P00352 8/20 0.34
KDM4E B2RXH2 7/20 0.34
MAPT P10636 5/20 0.34
LMNA P02545 4/20 0.34
MEN1 O00255 5/20 0.34
KMT2A Q03164 5/20 0.34
PKM P14618 1/20 0.34
ADORA2A P29274 1/20 0.34
ADORA1 P30542 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
RXFP1 Q9HBX9 1/20 0.34
HSD17B10 Q99714 3/20 0.34
TSHR P16473 2/20 0.34
MAPK1 P28482 2/20 0.34
CYP1A2 P05177 2/20 0.34
USP2 O75604 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10200119 0.92 KDM4E (0.38) HPGDSMN1; SMN2ALDH1A1KDM4EMAPT
SCHEMBL18294654 0.92 KDM4E (0.40) HPGDSMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL339857 0.86 KDM4E (0.39) HPGDSMN1; SMN2ALDH1A1KDM4EMAPT
SCHEMBL13232475 0.83 ALDH1A1 (0.49) HPGDSMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL339858 0.82 KDM4E (0.39) HPGDSMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL15233229 0.81 KDM4E (0.37) HPGDSMN1; SMN2ALDH1A1KDM4EMAPT
SCHEMBL13232467 0.79 MAPT (0.40) HPGDSMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL10200098 0.77 ALDH1A1 (0.37) HPGDSMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL13232463 0.77 NPC1 (0.36) HPGDSMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL340641 0.75 EDNRA (0.35) HPGDSMN1; SMN2NPC1RAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120015908-A1 SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES Efficient Pharma Management Corporate (TW) 2012-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015908-A1 SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES SLC22A8, ABCC8, CYP2C8 HPGD 1841/4885SMN1; SMN2 3441/4885NPC1 874/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.